Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 2, March-April, p. 213–219

Publication type: original article

Language: English

Creative Commons BY-NC-ND 3.0 Open Access

The Influence of Calcitriol and Tacalcitol on Proliferation of Fibroblasts Cultured from Nasal Polyps

Badanie wpływu kalcitriolu i tacalcitolu na proliferację fibroblastów otrzymanych z polipów nosowych

Beata Rostkowska−Nadolska1,, Małgorzata Latocha2,, Wojciech Gawron1,, Andrzej Kutner3,, Marek Bochnia1,

1 Department of Otorhinolaryngology, Silesian Piasts University of Medicine, Wroclaw, Poland

2 Department of Molecular Biology and Medical Genetics, Medical University of Silesia, Katowice, Poland

3 Pharmaceutical Institute, Warsaw, Poland

Abstract

Background. Recurrent polyposis resulting in the necessity of repeated polypectomy encouraged the search for new pharmacological therapeutic methods. At present, locally acting glycocorticosteroids have the greatest value in the treatment of nasal polyposis. Polyp growth is connected with inflammation and the proliferation of fibroblasts.
Objectives. An evaluation of the influence of calcitriol and tacalcitol on the proliferation of fibroblasts extracted from nasal polyps.
Material and Methods. The study involved 14 tissue samples of nasal polyps sampled during polypectomies. Testing was performed on the polyps cells after the sixth passage after the primary culture was established. Three days after the culture was started, nutrient medium without additional serum was added to the cells and after a further 24 hours the medium was replaced by nutrient medium with tacalcitol and calcitriol in defined concentrations.
Results. Tacalcitiol and calcitriol in vitro decreased the proliferation of fibroblasts extracted from nasal polyps. Inhibition was most effective at concentrations of 10–4 M and 10–3 M.
Conclusion. Experimental data suggest tacalcitiol to be more effective at the same concentration. This study may indicate the direction of further investigations in the potential pharmacological treatment of nasal polyps.

Streszczenie

Wprowadzenie. Nawracająca polipowatość nosa wymagająca powtarzania polipektomii u tego samego pacjenta zmusza do poszukiwania nowych farmakologicznych metod leczenia. Obecnie największe znaczenie w leczeniu zachowawczym polipów nosa mają miejscowo działające glikokortykosteroidy. Wzrost polipów jest związany z procesem zapalnym oraz proliferacją fibroblastów.
Cel pracy. Ocena wpływu kalcitriolu i tacalcitolu na proliferację fibroblastów otrzymanych z polipów nosa.
Materiał i metody. Do badań włączono 14 próbek tkanki pochodzącej z polipów nosa pobranych podczas zabiegu ich usunięcia. Badania zostały przeprowadzone po VI pasażu od założenia hodowli pierwotnej. Trzy dni po założeniu hodowli kultury były zanurzane w roztworze z dodatkiem takalcitiolu i kalcitriolu w zdefiniowanych stężeniach.
Wyniki. Tacalcitol i kalcitriol in vitro hamują wzrost fibroblastów pochodzących z polipów nosowych. Najbardziej skuteczne stężenia to 10–4 M oraz 10–3 M.
Wnioski. Uzyskane wyniki sugerują, że tacalcitol jest bardziej skuteczny w tych samych stężeniach. Obecne doświadczenia mogą wyznaczać dalszy kierunek badań dotyczących farmakologicznego leczenia polipów nosa.

Key words

nasal polyps, tacalcitol, calcitriol, fibroblasts, proliferation

Słowa kluczowe

polipy nosowe, tacalcitol, kalcitriol, fibroblasty, proliferacja

References (33)

  1. Kanai N, Denburg J, Jordana M, Dolovich J: Nasal polyp inflammation. Effect of topical nasal steroid. Am J Respir Crit Care Med 1994, 150(4), 1094–1100.
  2. Lildholdt T, Rundcrantz H, Lindqvist N: Efficacy of topical corticosteroid powder for nasal polyps; a double blind, placebo−controlled study of budesonide. Clin Otolaryngol 1995, Feb. 20(1), 26–30.
  3. Bruzzese N, Sica G, Iacopino F, Paludetti G, Schivano D, Nucera E, Scarano E, Patriarca G: Growth inhibition of fibroblasts from nasal polyps and normal skin by lysine acetysalcylate, Allergy 1998, 53, 431–434.
  4. Nonaka M, Pawankar R, Saji F, Yagi T: Effect of Roxitromycine on IL−8 synthesis and proliferation of nasal polyp fibroblasts. Acta Otolaryngol (Stockholm) 1998, suppl. 539, 71–75.
  5. Steinmeyer A, Kirch G, Neef G, Schwarz K: New synthetic vitamin D analogs with antiproliferative activities. Curr Pharm Des 2000, 6, 767–789.
  6. Opolski A Wietrzyk J, Siwińska A, Marcinkowska E, Chrobak A, Kutner A, Radzikowski C: Biological activity in vitro of side−chain modified analogues of calcitriol. Curr Pharm Des 2000, 6, 755–765.
  7. Arroyo CM, Kan RK, Burman DL, Kahler DW, Nelson MR, Corun CM, Guzman JJ, Broomfield CA: Regulation of 1alpha, 25−dihydroxyvitamin D3 on interleukin−6 and inteleukin−8 induced by sulfur mustard (HD) on human skin cells. Pharmacol Toxicol 2003, 92, 204–213.
  8. Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C: Pancreatic cancer cells express 25−Hydroxyvitamin D−1{alpha}−hydroxylase and their proliferation is inhibited by the prohormone 25−hydroxyvitamin D3. Carcinogenesis 2004, 25, 1015–1026.
  9. Yamada S, Yamamoto K, Masuno H: Structure−Function analysis of vitamin D and VDR model. Curr Pharm Des 2000, 6, 733–748.
  10. Jorgensen HL, Scholler J, Sand JC, Bjuring M, Hassager C, Christiansen C: Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone mass: Cross sectional and longitudinal population study. Br Med J 1996, 313, 586–590.
  11. Tsuji M, Fujii K, Nakno T, Nishii Y: 1 alpha−hydroxyvitamin D3 inhibits type II collagen−induced arthritis in rats, FEBS Lett 1994, 337, 248–250.
  12. Cantorna MT, Hayes CE, DeLuca HF: 1,25−Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998, 128, 68–72.
  13. Larsson P, Mattson L, Hjohnsson C: A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen−induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol 1998, 114, 277–283.
  14. Muller K, Bendtzen K: 1,25−Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996, 1, 68–71.
  15. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ: 1alpha,25−dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear−factor−kappaB−mediated interleukin−8 gene expression. Eur J Biochem 1997 15, 250, 63–71.
  16. Towers TL, Staeva TP, Freedman LP: A two−hit mechanism for vitamin D3−mediated transcriptional repression of the granulocyte−macrophage colony−stimulating factor gene: vitamin D receptor competes for NA binding with NFAT1 and stabilizes c−Jun. Moll Cell Biol 1999, 19, 4191–4199.
  17. Marcinkowska E, Kutner A, Radzikowski C: Cell differentiating and anti−proliferative activity of side−chain modified analogues of 1,25−dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1998, 67, 1, 71–78.
  18. Srivastava MD, DeLuca HF, Ambrus JL: Differentiation of neoplastic cells toward normal induced by vitamin D3 derivatives. Res Commun Chem Pathol Pharmacol 1994, 83, 115–123.
  19. Baudet C, Chevalier G, Naveilhan P, Binderup L, Brachet P, Wion D: Cytotoxic effects of 1 alpha. 25−dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Lett 1996, 100, 3–10.
  20. Castelijns F, Gerritsen MJP, Van Vlijmen−Willems IMJJ, Van Erp PJ, Van de Kerkhof PCM: Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of Tacalcitol ointment. Acta Derm Venereol (Stockh) 1999, 79, 111–114.
  21. Sato H, Ogino Y, Takagi H, Hata J, Asano S, Ohta T, Komoriya K: Pharmacological profiles of high−concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation and differentiation in mice. J Dermatol 2003, 30, 510–524.
  22. Gerritsen MJP, Boezemen JBM, van Vljmen−Willems IMJJ, Van de Kerkhof PCM: The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis; a placebo−controlled, double−blind study. Br J Dermatol 1994, 131, 57–63.
  23. Saati N, Ravid A, Liberman UA, Koren R: 1,25−dihydroxyvitamin D3 and agents that increase intracellular adenosine 3’,5’−monophosphate synergistically inhibit fibroblast proliferation. In Vitro Cell. Dev. Biol. Anim. 1997, 33, 310–314
  24. Lowe L, Hansen CM, Senaratne S, Colston KW: Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res 2003, 164, 99–110.
  25. Platz E, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannuci E: Plasma1,25−dihydroxyand 25−hydroxyvitamin D and adenoumatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 2000, 9, 1059–1065.
  26. Zabel M, Flig K, Gebarowska E, Surdyk−Zasada J: The effect of calcitriol and its analogues on proliferation and hormone expression in cultured cells of thyroid medullary carcinomas. Folia Morphol (Warsz) 2003, Nov, 62(4), 463–465. 218 B. ROSTKOWSKA−NADOLSKA et al.
  27. Stio M, Celli A, Lunghi B, Raugei G, Modesti A, Treves C: Vitamin D receptor in IMR−90 human fibroblasts and antiproliferative effect of 1,25−dihydroxyvitamin D3. Biochem Mol Biol Int 1997, 43, 1173–1181.
  28. Takahashi H, Ibe M, Kinouchi M, IshidaYamamoto A, Hashimoto Y, Lizuka H: Similary potent action of 1,25−dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003, 31, 21–28.
  29. Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K: Regulation of RANTES and IL−8 production In normal human dermal fibroblasts by active vitamin D3 (tacalcitol). Brit J Pharmacol 1998, 124, 1433–1438.
  30. Fukuoka M, Ogino TY, Sato H, Ohta T, Komoriya K, Nishioka K, Katayama I: RANTES expression in psoriatic skin, and regulation of RANTES and IL−8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol) Brit. J. of Dermatol. 1998, 138, 63–70.
  31. Yaron I, Meyer FA, Weisman Y, Yaron M: Effect of 1,25−Dihydroxyvitamin D3 on interleukin 1B actions and cell growth in human synovial fibroblast cultures. J Rheumatol 1993, 20, 1527–1532.
  32. Gniadecki R: Stimulation versus inhibition of keratinocytes growth by 1,25−dihydroxyvitamin D3: dependence on cell culture condition. J Invest Dermatol 1996, 106, 510–516.
  33. Studzinski GP, McLane JA, Uskokovic MR: Signaling pathway for vitamin D−induced differentiation: implications for therapy for proliferative and neoplastic disease. Crit Rev Eukaryot Gene Expr 1993, 3, 279–312.